Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

Marianna Sabatino, Seunghee Kim-Schulze, Monica C. Panelli, David Stroncek, Ena Wang, Bret Taback, Dae Won Kim, Gail DeRaffele, Zoltan Pos, Francesco M. Marincola, Howard L. Kaufman

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Purpose: High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified. Patients and Methods: To identify predictive biomarkers of clinical response, sera from patients treated with high-dose IL-2 were collected for analysis using a customized, multiplex antibody-targeted protein array platform that surveyed expression of soluble factors associated with tumor immunobiology. Soluble factors associated with clinical responses were analyzed using a multivariate permutation test, and survival outcomes were determined using Kaplan-Meier and log-rank tests. Results: A training set from 10 patients identified 68 potentially relevant soluble factors that were then tested in an independent validation set of 49 patients. Class comparison revealed a cluster of 11 biomarkers that were associated with therapeutic outcome. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response. In particular, high levels of these proteins were correlated with lack of clinical response and decreased overall survival. Conclusion: Serum VEGF and fibronectin are easily measured pretreatment biomarkers that could serve to exclude patients unlikely to respond to IL-2 therapy.

Original languageEnglish
Pages (from-to)2645-2652
Number of pages8
JournalJournal of Clinical Oncology
Volume27
Issue number16
DOIs
Publication statusPublished - 1 Jun 2009
Externally publishedYes

Fingerprint

Fibronectins
Vascular Endothelial Growth Factor A
Interleukin-2
Serum
Biomarkers
Therapeutics
Protein Array Analysis
Survival
Renal Cell Carcinoma
Melanoma
Antibodies
Neoplasms
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. / Sabatino, Marianna; Kim-Schulze, Seunghee; Panelli, Monica C.; Stroncek, David; Wang, Ena; Taback, Bret; Kim, Dae Won; DeRaffele, Gail; Pos, Zoltan; Marincola, Francesco M.; Kaufman, Howard L.

In: Journal of Clinical Oncology, Vol. 27, No. 16, 01.06.2009, p. 2645-2652.

Research output: Contribution to journalArticle

Sabatino, M, Kim-Schulze, S, Panelli, MC, Stroncek, D, Wang, E, Taback, B, Kim, DW, DeRaffele, G, Pos, Z, Marincola, FM & Kaufman, HL 2009, 'Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy', Journal of Clinical Oncology, vol. 27, no. 16, pp. 2645-2652. https://doi.org/10.1200/JCO.2008.19.1106
Sabatino, Marianna ; Kim-Schulze, Seunghee ; Panelli, Monica C. ; Stroncek, David ; Wang, Ena ; Taback, Bret ; Kim, Dae Won ; DeRaffele, Gail ; Pos, Zoltan ; Marincola, Francesco M. ; Kaufman, Howard L. / Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 16. pp. 2645-2652.
@article{8e63407c714b4a4aa24e1399a4ed268e,
title = "Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy",
abstract = "Purpose: High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified. Patients and Methods: To identify predictive biomarkers of clinical response, sera from patients treated with high-dose IL-2 were collected for analysis using a customized, multiplex antibody-targeted protein array platform that surveyed expression of soluble factors associated with tumor immunobiology. Soluble factors associated with clinical responses were analyzed using a multivariate permutation test, and survival outcomes were determined using Kaplan-Meier and log-rank tests. Results: A training set from 10 patients identified 68 potentially relevant soluble factors that were then tested in an independent validation set of 49 patients. Class comparison revealed a cluster of 11 biomarkers that were associated with therapeutic outcome. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response. In particular, high levels of these proteins were correlated with lack of clinical response and decreased overall survival. Conclusion: Serum VEGF and fibronectin are easily measured pretreatment biomarkers that could serve to exclude patients unlikely to respond to IL-2 therapy.",
author = "Marianna Sabatino and Seunghee Kim-Schulze and Panelli, {Monica C.} and David Stroncek and Ena Wang and Bret Taback and Kim, {Dae Won} and Gail DeRaffele and Zoltan Pos and Marincola, {Francesco M.} and Kaufman, {Howard L.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1200/JCO.2008.19.1106",
language = "English",
volume = "27",
pages = "2645--2652",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

AU - Sabatino, Marianna

AU - Kim-Schulze, Seunghee

AU - Panelli, Monica C.

AU - Stroncek, David

AU - Wang, Ena

AU - Taback, Bret

AU - Kim, Dae Won

AU - DeRaffele, Gail

AU - Pos, Zoltan

AU - Marincola, Francesco M.

AU - Kaufman, Howard L.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Purpose: High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified. Patients and Methods: To identify predictive biomarkers of clinical response, sera from patients treated with high-dose IL-2 were collected for analysis using a customized, multiplex antibody-targeted protein array platform that surveyed expression of soluble factors associated with tumor immunobiology. Soluble factors associated with clinical responses were analyzed using a multivariate permutation test, and survival outcomes were determined using Kaplan-Meier and log-rank tests. Results: A training set from 10 patients identified 68 potentially relevant soluble factors that were then tested in an independent validation set of 49 patients. Class comparison revealed a cluster of 11 biomarkers that were associated with therapeutic outcome. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response. In particular, high levels of these proteins were correlated with lack of clinical response and decreased overall survival. Conclusion: Serum VEGF and fibronectin are easily measured pretreatment biomarkers that could serve to exclude patients unlikely to respond to IL-2 therapy.

AB - Purpose: High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified. Patients and Methods: To identify predictive biomarkers of clinical response, sera from patients treated with high-dose IL-2 were collected for analysis using a customized, multiplex antibody-targeted protein array platform that surveyed expression of soluble factors associated with tumor immunobiology. Soluble factors associated with clinical responses were analyzed using a multivariate permutation test, and survival outcomes were determined using Kaplan-Meier and log-rank tests. Results: A training set from 10 patients identified 68 potentially relevant soluble factors that were then tested in an independent validation set of 49 patients. Class comparison revealed a cluster of 11 biomarkers that were associated with therapeutic outcome. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response. In particular, high levels of these proteins were correlated with lack of clinical response and decreased overall survival. Conclusion: Serum VEGF and fibronectin are easily measured pretreatment biomarkers that could serve to exclude patients unlikely to respond to IL-2 therapy.

UR - http://www.scopus.com/inward/record.url?scp=66849095271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66849095271&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.19.1106

DO - 10.1200/JCO.2008.19.1106

M3 - Article

VL - 27

SP - 2645

EP - 2652

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -